Study: Sustained use of antipsychotics increases Alzheimer's death risk

Prolonged use of antipsychotic medications on Alzheimer's patients is associated with a significantly increased risk of death, according to a new British study.

The long-term study, conducted by researchers at King's College London, followed 128 Alzheimer's patients for three years. One group was treated with antipsychotic medication, while another was given a placebo. After one year, researchers found similar survival rates among the groups. But after three years, the numbers became more drastic: Only 30% of those on antipsychotics were alive, compared with 59% of those taking a placebo, according to the research. Overall, there was a 42% lower risk of death for the placebo group.

Such off-label use of antipsychotics to treat Alzheimer's patients is common practice in nursing homes. Researchers do not dispute that short term use of the drugs can be beneficial for the patients. The substantial increase in long-term mortality risk, however, emphasizes the need to put an end to prolonged use of the meds, according to report authors. Their research appears online in the Jan. 8 edition of The Lancet Neurology.

More in News

Government agency launches health IT webpage for long-term care providers

Government agency launches health IT webpage for long-term ...

The Office of the National Coordinator for Health Information Technology has unveiled a new webpage with information and resources for long-term and post-acute (LTPAC) providers.

FDA responds to provider pressure, backs off stricter control of fecal transplants ...

Individuals with treatment-resistant Clostridium difficile can undergo fecal transplants after giving informed consent, the Food and Drug Administration recently announced. This is a victory for providers, who pushed back after the FDA recently announced it would tighten regulations around the transplants.

Judge denies Omnicare's 'untimely' motion to disqualify whistleblower in nursing home kickbacks ...

Omnicare has failed to disqualify a whistleblower who alleges the long-term care pharmacy paid kickbacks to nursing homes, ruled a district court judge.